Development of renal injury during the use of antibiotic in a Intensive Care Unit
Keywords:
Acute Renal Injury, Intensive Care Units, Carbapenemics, AminoglycosidesAbstract
Introduction: Acute Renal Injury (LRA) is a systemic event, which mainly affects patients with advanced age and a longer time of hospitalization, being this group having a greater predisposition to death. Objective: To characterize the profile of the patient who developed AKI, to determine the extent of the lesion, to identify which antibiotics are related to AKI and to relate the mortality rate to AKI. Materials and methods: A cross-sectional observational study was carried out with data from the electronic medical records of patients admitted to the intensive care unit from April to September 2017, after which a statistical analysis of the data collected was performed. Results: In this study, 67.27% of the patients developed AKI. The majority of the patients who presented AKI were men, with a mean age of 56 years, a period of hospitalization of more than 10 days, and a mortality risk of 73%. The antibiotics associated with renal injury were Carbapenemics and Aminoglycosides. Regarding the extent of renal injury, there was a higher prevalence of stage 3 of the Acute Kidney Injury Network (AKIN) score. Regarding the clinical outcome, the death rate of patients with AKI was of 35.13%. Conclusion: The present study presented a profile of patients who developed renal damage consistent with what is found in the literature, it also adds the risk of mortality from the Apache II score, which shows how much the risk of mortality is increased in patients who develop ARF related to the use of antibiotics.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Revista de Saúde Pública de Mato Grosso do Sul
This work is licensed under a Creative Commons Attribution 4.0 International License.
O (s) Autor (es) declara (m) que ao submeter um manuscrito na Revista de Saúde Pública de Mato Grosso do Sul, concorda (m) com os termos da Declaração de Direito Autoral e autoriza (m) a Revista de Saúde Pública de Mato Grosso do Sul a publicar o manuscrito sob a licença Creative Commons Atribuição 4.0 Internacional e identificar-se como veículo de sua publicação original.